Elena Altieri

Garbagnate Milanese, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study.

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study.

Journal: The World Allergy Organization journal

Published: August 28, 2025

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single-centre study.

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single-centre study.

Journal: British journal of clinical pharmacology

Published: August 11, 2025

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study.

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study.

Journal: ERJ open research

Published: July 01, 2025

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study.

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study.

Journal: Frontiers in allergy

Published: September 24, 2024

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.

Journal: Journal of asthma and allergy

Published: November 08, 2023

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.

Journal: Respiratory research

Published: March 06, 2023

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.

Journal: Journal of asthma and allergy

Published: July 25, 2022

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.

Journal: Frontiers in medicine

Published: May 23, 2022

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis.

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis.

Journal: Frontiers in allergy

Published: February 22, 2022

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.

Journal: Respiratory research

Published: August 06, 2021

Resection rate of lung cancer in Teesside (UK) and Varese (Italy): a comparison after implementation of the National Cancer Plan.

Resection rate of lung cancer in Teesside (UK) and Varese (Italy): a comparison after implementation of the National Cancer Plan.

Journal: Thorax

Published: July 15, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026